OBJECTIVE: Using moderate or ultra-hypofractionation, which is also known as stereotactic body radiotherapy (SBRT) for treatment of localized prostate cancer patients has been increased. We present our preliminary results on the clinical utilization of MRI-guided adaptive radiotherapy (MRgRT) for prostate cancer patients with the workflow, dosimetric parameters, toxicities and prostate-specific antigen (PSA) response. METHODS: 50 prostate cancer patients treated with ultra-hypofractionation were included in the study. Treatment was performed with intensity-modulated radiation therapy (step and shoot) technique and daily plan adaptation using MRgRT. The SBRT consisted of 36.25 Gy in 5 fractions with a 7.25 Gy fraction size. The time for workflow steps was documented. Patients were followed for the acute and late toxicities and PSA response. RESULTS: The median follow-up for our cohort was 10 months (range between 3 and 29 months). The median age was 73.5 years (range between 50 and 84 years). MRgRT was well tolerated by all patients. Acute genitourinary (GU) toxicity rate of Grade 1 and Grade 2 was 28 and 36%, respectively. Only 6% of patients had acute Grade 1 gastrointestinal (GI) toxicity and there was no Grade ≥ 2 GI toxicity. To date, late Grade 1 GU toxicity was experienced by 24% of patients, 2% of patients experienced Grade 2 GU toxicity and 6% of patients reported Grade 2 GI toxicity. Due to the short follow-up, PSA nadir has not been reached yet in our cohort. CONCLUSION: In conclusion, MRgRT represents a new method for delivering SBRT with markerless soft tissue visualization, online adaptive planning and real-time tracking. Our study suggests that ultra-hypofractionation has an acceptable acute and very low late toxicity profile. ADVANCES IN KNOWLEDGE: MRgRT represents a new markerless method for delivering SBRT for localized prostate cancer providing online adaptive planning and real-time tracking and acute and late toxicity profile is acceptable.
OBJECTIVE: Using moderate or ultra-hypofractionation, which is also known as stereotactic body radiotherapy (SBRT) for treatment of localized prostate cancer patients has been increased. We present our preliminary results on the clinical utilization of MRI-guided adaptive radiotherapy (MRgRT) for prostate cancer patients with the workflow, dosimetric parameters, toxicities and prostate-specific antigen (PSA) response. METHODS: 50 prostate cancer patients treated with ultra-hypofractionation were included in the study. Treatment was performed with intensity-modulated radiation therapy (step and shoot) technique and daily plan adaptation using MRgRT. The SBRT consisted of 36.25 Gy in 5 fractions with a 7.25 Gy fraction size. The time for workflow steps was documented. Patients were followed for the acute and late toxicities and PSA response. RESULTS: The median follow-up for our cohort was 10 months (range between 3 and 29 months). The median age was 73.5 years (range between 50 and 84 years). MRgRT was well tolerated by all patients. Acute genitourinary (GU) toxicity rate of Grade 1 and Grade 2 was 28 and 36%, respectively. Only 6% of patients had acute Grade 1 gastrointestinal (GI) toxicity and there was no Grade ≥ 2 GI toxicity. To date, late Grade 1 GU toxicity was experienced by 24% of patients, 2% of patients experienced Grade 2 GU toxicity and 6% of patients reported Grade 2 GI toxicity. Due to the short follow-up, PSA nadir has not been reached yet in our cohort. CONCLUSION: In conclusion, MRgRT represents a new method for delivering SBRT with markerless soft tissue visualization, online adaptive planning and real-time tracking. Our study suggests that ultra-hypofractionation has an acceptable acute and very low late toxicity profile. ADVANCES IN KNOWLEDGE: MRgRT represents a new markerless method for delivering SBRT for localized prostate cancer providing online adaptive planning and real-time tracking and acute and late toxicity profile is acceptable.
Authors: Anders Widmark; Adalsteinn Gunnlaugsson; Lars Beckman; Camilla Thellenberg-Karlsson; Morten Hoyer; Magnus Lagerlund; Jon Kindblom; Claes Ginman; Bengt Johansson; Kirsten Björnlinger; Mihajl Seke; Måns Agrup; Per Fransson; Björn Tavelin; David Norman; Björn Zackrisson; Harald Anderson; Elisabeth Kjellén; Lars Franzén; Per Nilsson Journal: Lancet Date: 2019-06-18 Impact factor: 79.321
Authors: Angela U Pathmanathan; Nicholas J van As; Linda G W Kerkmeijer; John Christodouleas; Colleen A F Lawton; Danny Vesprini; Uulke A van der Heide; Steven J Frank; Simeon Nill; Uwe Oelfke; Marcel van Herk; X Allen Li; Kathryn Mittauer; Mark Ritter; Ananya Choudhury; Alison C Tree Journal: Int J Radiat Oncol Biol Phys Date: 2017-10-26 Impact factor: 7.038
Authors: Michael Pinkawa; Branka Asadpour; Jaroslav Siluschek; Bernd Gagel; Marc D Piroth; Cengiz Demirel; Michael J Eble Journal: Radiother Oncol Date: 2007-05-17 Impact factor: 6.280
Authors: Christopher R King; Debra Freeman; Irving Kaplan; Donald Fuller; Giampaolo Bolzicco; Sean Collins; Robert Meier; Jason Wang; Patrick Kupelian; Michael Steinberg; Alan Katz Journal: Radiother Oncol Date: 2013-09-20 Impact factor: 6.280
Authors: Darren M C Poon; Bin Yang; Hui Geng; Oi Lei Wong; Sin Ting Chiu; Kin Yin Cheung; Siu Ki Yu; George Chiu; Jing Yuan Journal: J Cancer Res Clin Oncol Date: 2022-02-24 Impact factor: 4.553
Authors: Berend J Slotman; Mary Ann Clark; Enis Özyar; Myungsoo Kim; Jun Itami; Agnès Tallet; Jürgen Debus; Raphael Pfeffer; PierCarlo Gentile; Yukihiro Hama; Nicolaus Andratschke; Olivier Riou; Philip Camilleri; Claus Belka; Magali Quivrin; BoKyong Kim; Anders Pedersen; Mette van Overeem Felter; Young Il Kim; Jin Ho Kim; Martin Fuss; Vincenzo Valentini Journal: Radiat Oncol Date: 2022-08-22 Impact factor: 4.309
Authors: Johanna Sprenger; Marcel Bengs; Stefan Gerlach; Maximilian Neidhardt; Alexander Schlaefer Journal: Int J Comput Assist Radiol Surg Date: 2022-05-21 Impact factor: 3.421